Compare EWTX & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | GTLB |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 2021 | 2021 |
| Metric | EWTX | GTLB |
|---|---|---|
| Price | $45.98 | $49.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 27 |
| Target Price | ★ $39.00 | $37.17 |
| AVG Volume (30 Days) | 1.0M | ★ 5.2M |
| Earning Date | 05-07-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $955,224,000.00 |
| Revenue This Year | N/A | $18.72 |
| Revenue Next Year | N/A | $16.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $14.25 | $18.73 |
| 52 Week High | $48.51 | $55.55 |
| Indicator | EWTX | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 64.27 |
| Support Level | $41.31 | $46.01 |
| Resistance Level | $48.40 | $55.55 |
| Average True Range (ATR) | 2.00 | 2.23 |
| MACD | 0.26 | -0.12 |
| Stochastic Oscillator | 66.26 | 45.99 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.